PrestoDoctor Expands Medical Marijuana Recommendation Telemedicine Service to Missouri
July 03, 2019 at 04:20 AM EDT
MESQUITE, NV / ACCESSWIRE / July 3, 2019 / Cannabis Sativa, Inc. (OTCQB: CBDS) is proud to announce that PrestoDoctor (https://prestodoctor.com/) is now offering their online Medical recommendation services to cannabis patients in the "Show Me" state of Missouri. PrestoDoctor, the #1 patient-rated medical cannabis telemedicine service brings years of experience and compassionate telemedicine care to the emerging Missouri medical cannabis market. The Company's Co-Founder & COO Rob Tankson, shares his excitement about the expansion, stating "our proprietary telemedicine portal is now providing Missouri's cannabis patients easy and confidential access and education with an online appointment with a licensed medical doctor."
On November 6, 2018, Missouri voters enacted medical cannabis legalization through Amendment 2 with 61% of the vote. Amendment 2 requires that the state begin taking applications for qualifying patients no later than June 4, 2019.
PrestoDoctor has provided medical recommendations to over 100,000 patients in five states. The state of New York and the newly-opened Oklahoma market have exhibited robust demand and the Company expects further growth in 2019 and beyond.
PrestoDoctor launched in California in the summer of 2015, and has since expanded into Nevada, New York, Oklahoma and Missouri. PrestoDoctor has facilitated over a hundred thousand appointments and maintains the highest customer satisfaction rating for any telemedicine service online. PrestoDoctor has over 4,000 5-star reviews, and is the first medical marijuana company to be accepted into the American Telemedicine Association. PrestoDoctor is HIPAA and HITECH compliant. PrestoDoctor plans to continue to expand its services in 2019.
About Cannabis Sativa, Inc.:
Cannabis Sativa, Inc. ("CBDS") is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the "hi" and "White Rabbit" brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, a U.S. Patent for a marijuana lozenge; a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery and trade secret formulas and processes, and operates subsidiaries including: PrestoDoctor® (https://prestodoctor.com), Wild Earth Naturals® (https://wildearthnaturals.com), and iBudtender (https://ibudtender.com). The Company is the official licensee for Virgin Mary Jane Brand (https://virginmaryjanebrand.com). In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
SOURCE: Cannabis Sativa, Inc.
View source version on accesswire.com: